From GlobeNewswire: 2025-03-26 01:00:00

BioVersys AG announced positive Phase 2 trial results for BV100, showing excellent safety and efficacy data. They completed a successful IPO on the SIX Swiss Exchange, raising CHF 76.7 million. Plans include initiating a Phase 3 program for BV100 and additional Phase 2 studies for Alpibectir in Tuberculosis. Financially, they reported an operating income of CHF 1.2 million and a net loss of CHF 18.7 million for 2024. Successful financing activities included a Series C financing round of CHF 15 million and a USD 6 million investment from GIBF.
In 2024, BioVersys’ lead candidate BV100 showed strong efficacy in a Phase 2 VABP trial, halving the mortality rate in patients with carbapenem-resistant infections. BV100 was generally safe and effective in patients with totally drug-resistant infections. Alpibectir also showed strong proof of concept in a Phase 2a EBA trial. Preclinical candidates BV200 and BV500 showed progress in development as well.
Financially, BioVersys recognized an operating income of CHF 1.2 million and incurred operating expenses of CHF 19.9 million in 2024. They raised approximately CHF 20 million through financing activities, increasing their cash position to CHF 32.6 million. They reported an operating loss of CHF 18.7 million and a net loss of CHF 18.7 million for 2024.
BioVersys successfully completed an IPO on the SIX Swiss Exchange in Q1 2025, strengthening their financial position. They plan to initiate a Phase 3 trial for BV100 in the second half of 2025 and conduct additional Phase 2 studies for Alpibectir. The company expects an operating loss in the range of CHF 32.0 to CHF 35.0 million for 2025.
BioVersys is a biopharmaceutical company focused on antibacterial products for MDR infections. They aim to address the unmet need for new treatments against resistant bacterial infections. The company’s pipeline includes candidates targeting Acinetobacter baumannii and tuberculosis. They are located in Basel, Switzerland.



Read more at GlobeNewswire:: BioVersys Reports Corporate Highlights and Key Financials